Musi wa11 Gumiguru 2024, Hympavzi (marstacimab-hncq), munhu monoclonal antibody akanangana ne "tissue factor pathway inhibitor" akagamuchira US. FDAMvumo semushonga mutsva wekudzivirira kubuda ropa muvanhu vane hemophilia A kana hemophilia B.
Pakutanga, musi wa19 Gunyana 2024, Hympavzi akapihwa mvumo yekushambadzira neEuropean Medicine Agency (EMA) yekudzivirira kubuda kweropa muvarwere vane hemophilia A kana B.
Hemophilia A chirwere chekugara nhaka ropa chinokonzerwa nekushaikwa kweropa rinogwamba VIII nepo hemophilia B ichikonzerwa nekusakwana kwegwamba re IX. Mamiriro acho ese ari maviri anorapwa nekutsiva majekiseni akarasika ekuvhara ropa.
Hympavzi inodzivirira kubuda kweropa nemaitiro akasiyana. Inonangana neprotein inowanzoitika yeanticoagulation inonzi "tissue factor pathway inhibitor" uye inoderedza basa rayo rekudzivirira nekudaro ichiwedzera huwandu hwethrombin.
Mushonga mutsva uyu unopa nzira itsva yekurapa kuvarwere. Iyi ndiyo yekutanga, isiri-chinhu uye kamwe-pasvondo kurapwa kwehemophilia B.
Mvumo yeHympavzi yeFDA yakavakirwa pamhedzisiro inogutsa kubva kuchikamu chechitatu chemuyedzo wekiriniki yakawanda yakaongorora kuchengetedzeka kwayo uye kushanda kwayo muvachiri kuyaruka nevatori vechikamu vechikuru vane makore gumi nemaviri kusvika <3 makore vane hemophilia A yakaipisisa kana kuti ine mwero kusvika kune yakanyanya hemophilia B.
***
Sources:
- FDA Nhau yakabudiswa - FDA Inobvumira Kurapwa Kutsva kweHemophilia A kana B. Yakatumirwa musi wa11 Gumiguru 2024. Inowanikwa pa https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hemophilia-or-b
- EMA. Hympavzi – Marstacimab. Inowanikwa pa https://www.ema.europa.eu/en/medicines/human/EPAR/hympavzi
***
